IDIBAPS, Institut d'Investigacions Biomèdiques August Pi i Sunyer

Resultats de l'any: 2010 2009 2008 2007

Factor d'impacte: mitjana: 7.96, total: 246.62

Articles de l'any 2010

Original

• Retransplantation in patients with hepatitis C recurrence after liver transplantation

  Carrion JA, Navasa M, Forns X
  J HEPATOL. 2010; 53: 962-970. IF: 7.818

• ATG-Fresenius Treatment and Low-Dose Tacrolimus: Results of a Randomized Controlled Trial in Liver Transplantation

  Benitez CE, Puig-Pey I, Lopez M, Martinez-Llordella M, Lozano JJ, Bohne F, Londono MC, Garcia-Valdecasas JC, Bruguera M, Navasa M, Rimola A, Sanchez-Fueyo A
  AM J TRANSPLANT. 2010; 10: 2296-2304. IF: 6.433

• Long-Term Experience With Kidney Transplantation From Hepatitis C-Positive Donors Into Hepatitis C-Positive Recipients

  Morales JM, Campistol JM, Dominguez-Gil B, Andres A, Esforzado N, Oppenheimer F, Castellano G, Fuertes A, Bruguera M, Praga M
  AM J TRANSPLANT. 2010; 10: 2453-2462. IF: 6.433

• Peginterferon Plus Ribavirin and Sustained Virological Response in HCV-Related Cirrhosis: Outcomes and Factors Predicting Response

  Fernandez-Rodriguez CM, Alonso S, Martinez SM, Forns X, Sanchez-Tapias JM, Rincon D, Rodriguez-Caravaca G, Barcena R, Serra MA, Romero-Gomez M, Fernandez I, Garcia-Samaniego J, Fuente J, Sola R, Moreno-Otero R, Planas R
  AM J GASTROENTEROL. 2010; 105: 2164-2172. IF: 6.012

• Double-blind, randomized, placebo-controlled Phase I Clinical Trial of the therapeutical antituberculous vaccine RUTI (R)

  Vilaplana C, Montane E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J
  VACCINE. 2010; 28: 1106-1116. IF: 3.616

• Combined liver-kidney transplantation in patients with cirrhosis and chronic kidney disease

  Baccaro ME, Pepin MN, Guevara M, Colmenero J, Torregrosa JV, Martin-Llahi M, Sola E, Esforzado N, Fuster J, Campistol JM, Arroyo V, Navasa M, Garcia-Valdecasas J, Gines P
  NEPHROL DIAL TRANSPL. 2010; 25: 2356-2363. IF: 3.306

• Hepatitis C virus superinfection of liver grafts: a detailed analysis of early exclusion of non-dominant virus strains

  Ramirez S, Perez-Del-Pulgar S, Carrion JA, Coto-Llerena M, Mensa L, Dragun J, Garcia-Valdecasas JC, Navasa M, Forns X
  J GEN VIROL. 2010; 91: 1183-1188. IF: 3.26

• Use of non-specific intravenous human immunoglobulins in Spanish hospitals; need for a hospital protocol

  Ruiz-Antoran B, Escasany AA, Ferraz AV, Carreras ID, Riba N, Escudero SM, Costa J, Santiago MBS, Laredo L, Quintana JAD, Castillo JR, Abad-Santos F, Herrera CP, DeRada BSD, Ontanon EG
  EUR J CLIN PHARMACOL . 2010; 66: 633-641. IF: 2.743

• Prevalence of Protective Measles Virus Antibody Levels in Umbilical Cord Blood Samples in Catalonia, Spain

  Plans P, Costa J, Dominguez A, Torner N, Borras E, Plasencia A
  CLIN VACCINE IMMUNOL. 2010; 17: 691-694. IF: 2.373

• Serum Fibrosis Markers Identify Patients With Mild and Progressive Hepatitis C Recurrence After Liver Transplantation

  Carrion JA, Fernandez-Varo G, Bruguera M, Garcia-Pagan JC, Garcia-Valdecasas JC, Perez-Del-Pulgar S, Forns X, Jimenez W, Navasa M
  GASTROENTEROLOGY. 2010; 138: 147-158. IF: 12.899

• Liver Stiffness Identifies Two Different Patterns of Fibrosis Progression in Patients with Hepatitis C Virus Recurrence After Liver Transplantation

  Carrion JA, Torres F, Crespo G, Miquel R, Garcia-Valdecasas JC, Navasa M, Forns X
  HEPATOLOGY. 2010; 51: 23-34. IF: 10.84

• Bacterial DNA Translocation Is Associated With Systemic Circulatory Abnormalities and Intrahepatic Endothelial Dysfunction in Patients With Cirrhosis

  Bellot P, Garcia-Pagan JC, Frances R, Abraldes JG, Navasa M, Perez-Mateo M, Such J, Bosch J
  HEPATOLOGY. 2010; 52: 2044-2052. IF: 10.84

• Ghrelin Attenuates Hepatocellular Injury and Liver Fibrogenesis in Rodents and Influences Fibrosis Progression in Humans

  Moreno M, Chaves JF, Sancho-Bru P, Ramalho F, Ramalho LN, Mansego ML, Ivorra C, Dominguez M, Conde L, Millan C, Mari M, Colmenero J, Lozano JJ, Jares P, Vidal J, Forns X, Arroyo V, Caballeria J, Gines P, Bataller R
  HEPATOLOGY. 2010; 51: 974-985. IF: 10.84

• Severe acute hepatitis in the dress syndrome: Report of two cases

  Lens S, Crespo G, Carrion JA, Miquel R, Navasa M
  ANN HEPATOL. 2010; 9: 198-201. IF: 1.674

• Klebsiella pneumoniae Infection in Solid Organ Transplant Recipients: Epidemiology and Antibiotic Resistance

  Linares L, Cervera C, Hoyo I, Sanclemente G, Marco F, Cofan F, Ricart MJ, Navasa M, Moreno A
  TRANSPL P. 2010; 42: 2941-2943. IF: 0.994

Editorials

• Treating hepatitis C in patients with cirrhosis: The effort is worth it

  Forns X, Bruix J
  J HEPATOL. 2010; 52: 624-626. IF: 7.818

• Multifaceted Perspective of the Waiting List for Liver Transplantation: The Value of Pharmacokinetic Models

  Navasa M, Bruix J
  HEPATOLOGY. 2010; 51: 12-15. IF: 10.84

Multicèntrics

• Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

  Kwo PY, Lawitz EJ, Mccone J, Schiff ER, Vierling JM, Pound D, Davis MN, Galati JS, Gordon SC, Ravendhran N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhri E, Albrecht JK
  LANCET. 2010; 376: 705-716. IF: 30.758

• Albinterferon Alfa-2b Was Not Inferior to Pegylated Interferon-alpha in a Randomized Trial of Patients With Chronic Hepatitis C Virus Genotype 1

  Zeuzem S, Sulkowski MS, Lawitz EJ, Rustgi VK, Rodriguez-Torres M, Bacon BR, Grigorescu M, Tice AD, Lurie Y, Cianciara J, Muir AJ, Cronin PW, Pulkstenis E, Subramanian GM, Mchutchison JG
  GASTROENTEROLOGY. 2010; 139: 1257-1266. IF: 12.899

Guies clíniques

• EASL Clinical Practice Guidelines: Management of chronic hepatitis B

  Forns X, Et AL
  J HEPATOL. 2010; 50: 227-242. IF: 7.818

Tornar